CTLA4 and neoplasm: Surprisingly, the studies demonstrated the predictive role of tumor cell HLA class I expression in melanoma patients treated with the CTLA-4 inhibitor ipilimumab [24,25] but not in those receiving PD-1 blocking agents [23,24].